Future prospects of brain stimulation.
Identifieur interne : 001294 ( PubMed/Curation ); précédent : 001293; suivant : 001295Future prospects of brain stimulation.
Auteurs : A L Benabid [France] ; A. Koudsié ; P. Pollak ; P. Kahane ; S. Chabardes ; E. Hirsch ; C. Marescaux ; A. BenazzouzSource :
- Neurological research [ 0161-6412 ] ; 2000.
English descriptors
- KwdEn :
- MESH :
- adverse effects : Electric Stimulation Therapy.
- therapy : Parkinson Disease, Parkinsonian Disorders.
- Animals, Brain, Haplorhini, Humans, Rats, Thalamus.
Abstract
Chronic high frequency (130 Hz) stimulation (HFS) of the thalamic target Vim has replaced thalamotomy as a treatment of tremor of various origins and was extended to two other targets (Subthalamic nucleus (STN) and the medial pallidus (GPi)), since 1993 based on recent experimental data in rats and monkeys. STN appears to be a target of major interest, able to control the three cardinal symptoms and to allow the decrease or suppression of levodopa treatment, which then suppresses also levodopa induced dyskinesias. The mechanisms of action of HFS are not fully understood, but are definitely related to high frequency and are probably different depending on the target. Inhibition of cellular activity or of network functions could be induced, by jamming of a retroactive loop for tremor, or by shutdown of neurotransmitter release in STN. All cardinal symptoms are alleviated from tremor to akinesia and rigidity. The effects remain stable over more than five years chronic HFS of STN, as the method of choice when a surgical procedure is indicated for the treatment of Parkinson's disease and even more when a bilateral procedure is necessary. Recent data show that STN stimulation could be useful in the treatment of dystonia as well as some forms of epilepsies. It is therefore possible that DAS in STN as well as in other targets could become a potent therapeutic tool in the future for neurological disorders. The future of brain stimulation will depend on new technologies (new circuits, electrodes, web based programmers), waveforms (alternatives to square waves, random distribution), targets (hypothalamic nuclei, locus coeruleus) and indications (dystonia, epilepsy, eating disorders.
PubMed: 10769816
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001335
Links to Exploration step
pubmed:10769816Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Future prospects of brain stimulation.</title>
<author><name sortKey="Benabid, A L" sort="Benabid, A L" uniqKey="Benabid A" first="A L" last="Benabid">A L Benabid</name>
<affiliation wicri:level="1"><nlm:affiliation>Inserm U 318, CHU of Grenoble, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Inserm U 318, CHU of Grenoble</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Koudsie, A" sort="Koudsie, A" uniqKey="Koudsie A" first="A" last="Koudsié">A. Koudsié</name>
</author>
<author><name sortKey="Pollak, P" sort="Pollak, P" uniqKey="Pollak P" first="P" last="Pollak">P. Pollak</name>
</author>
<author><name sortKey="Kahane, P" sort="Kahane, P" uniqKey="Kahane P" first="P" last="Kahane">P. Kahane</name>
</author>
<author><name sortKey="Chabardes, S" sort="Chabardes, S" uniqKey="Chabardes S" first="S" last="Chabardes">S. Chabardes</name>
</author>
<author><name sortKey="Hirsch, E" sort="Hirsch, E" uniqKey="Hirsch E" first="E" last="Hirsch">E. Hirsch</name>
</author>
<author><name sortKey="Marescaux, C" sort="Marescaux, C" uniqKey="Marescaux C" first="C" last="Marescaux">C. Marescaux</name>
</author>
<author><name sortKey="Benazzouz, A" sort="Benazzouz, A" uniqKey="Benazzouz A" first="A" last="Benazzouz">A. Benazzouz</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2000">2000</date>
<idno type="RBID">pubmed:10769816</idno>
<idno type="pmid">10769816</idno>
<idno type="wicri:Area/PubMed/Corpus">001335</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001335</idno>
<idno type="wicri:Area/PubMed/Curation">001294</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001294</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Future prospects of brain stimulation.</title>
<author><name sortKey="Benabid, A L" sort="Benabid, A L" uniqKey="Benabid A" first="A L" last="Benabid">A L Benabid</name>
<affiliation wicri:level="1"><nlm:affiliation>Inserm U 318, CHU of Grenoble, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Inserm U 318, CHU of Grenoble</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Koudsie, A" sort="Koudsie, A" uniqKey="Koudsie A" first="A" last="Koudsié">A. Koudsié</name>
</author>
<author><name sortKey="Pollak, P" sort="Pollak, P" uniqKey="Pollak P" first="P" last="Pollak">P. Pollak</name>
</author>
<author><name sortKey="Kahane, P" sort="Kahane, P" uniqKey="Kahane P" first="P" last="Kahane">P. Kahane</name>
</author>
<author><name sortKey="Chabardes, S" sort="Chabardes, S" uniqKey="Chabardes S" first="S" last="Chabardes">S. Chabardes</name>
</author>
<author><name sortKey="Hirsch, E" sort="Hirsch, E" uniqKey="Hirsch E" first="E" last="Hirsch">E. Hirsch</name>
</author>
<author><name sortKey="Marescaux, C" sort="Marescaux, C" uniqKey="Marescaux C" first="C" last="Marescaux">C. Marescaux</name>
</author>
<author><name sortKey="Benazzouz, A" sort="Benazzouz, A" uniqKey="Benazzouz A" first="A" last="Benazzouz">A. Benazzouz</name>
</author>
</analytic>
<series><title level="j">Neurological research</title>
<idno type="ISSN">0161-6412</idno>
<imprint><date when="2000" type="published">2000</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Brain</term>
<term>Electric Stimulation Therapy (adverse effects)</term>
<term>Haplorhini</term>
<term>Humans</term>
<term>Parkinson Disease (therapy)</term>
<term>Parkinsonian Disorders (therapy)</term>
<term>Rats</term>
<term>Thalamus</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Electric Stimulation Therapy</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Parkinson Disease</term>
<term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Brain</term>
<term>Haplorhini</term>
<term>Humans</term>
<term>Rats</term>
<term>Thalamus</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Chronic high frequency (130 Hz) stimulation (HFS) of the thalamic target Vim has replaced thalamotomy as a treatment of tremor of various origins and was extended to two other targets (Subthalamic nucleus (STN) and the medial pallidus (GPi)), since 1993 based on recent experimental data in rats and monkeys. STN appears to be a target of major interest, able to control the three cardinal symptoms and to allow the decrease or suppression of levodopa treatment, which then suppresses also levodopa induced dyskinesias. The mechanisms of action of HFS are not fully understood, but are definitely related to high frequency and are probably different depending on the target. Inhibition of cellular activity or of network functions could be induced, by jamming of a retroactive loop for tremor, or by shutdown of neurotransmitter release in STN. All cardinal symptoms are alleviated from tremor to akinesia and rigidity. The effects remain stable over more than five years chronic HFS of STN, as the method of choice when a surgical procedure is indicated for the treatment of Parkinson's disease and even more when a bilateral procedure is necessary. Recent data show that STN stimulation could be useful in the treatment of dystonia as well as some forms of epilepsies. It is therefore possible that DAS in STN as well as in other targets could become a potent therapeutic tool in the future for neurological disorders. The future of brain stimulation will depend on new technologies (new circuits, electrodes, web based programmers), waveforms (alternatives to square waves, random distribution), targets (hypothalamic nuclei, locus coeruleus) and indications (dystonia, epilepsy, eating disorders.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10769816</PMID>
<DateCreated><Year>2000</Year>
<Month>06</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted><Year>2000</Year>
<Month>06</Month>
<Day>08</Day>
</DateCompleted>
<DateRevised><Year>2006</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0161-6412</ISSN>
<JournalIssue CitedMedium="Print"><Volume>22</Volume>
<Issue>3</Issue>
<PubDate><Year>2000</Year>
<Month>Apr</Month>
</PubDate>
</JournalIssue>
<Title>Neurological research</Title>
<ISOAbbreviation>Neurol. Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Future prospects of brain stimulation.</ArticleTitle>
<Pagination><MedlinePgn>237-46</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Chronic high frequency (130 Hz) stimulation (HFS) of the thalamic target Vim has replaced thalamotomy as a treatment of tremor of various origins and was extended to two other targets (Subthalamic nucleus (STN) and the medial pallidus (GPi)), since 1993 based on recent experimental data in rats and monkeys. STN appears to be a target of major interest, able to control the three cardinal symptoms and to allow the decrease or suppression of levodopa treatment, which then suppresses also levodopa induced dyskinesias. The mechanisms of action of HFS are not fully understood, but are definitely related to high frequency and are probably different depending on the target. Inhibition of cellular activity or of network functions could be induced, by jamming of a retroactive loop for tremor, or by shutdown of neurotransmitter release in STN. All cardinal symptoms are alleviated from tremor to akinesia and rigidity. The effects remain stable over more than five years chronic HFS of STN, as the method of choice when a surgical procedure is indicated for the treatment of Parkinson's disease and even more when a bilateral procedure is necessary. Recent data show that STN stimulation could be useful in the treatment of dystonia as well as some forms of epilepsies. It is therefore possible that DAS in STN as well as in other targets could become a potent therapeutic tool in the future for neurological disorders. The future of brain stimulation will depend on new technologies (new circuits, electrodes, web based programmers), waveforms (alternatives to square waves, random distribution), targets (hypothalamic nuclei, locus coeruleus) and indications (dystonia, epilepsy, eating disorders.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Benabid</LastName>
<ForeName>A L</ForeName>
<Initials>AL</Initials>
<AffiliationInfo><Affiliation>Inserm U 318, CHU of Grenoble, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Koudsié</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y"><LastName>Pollak</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y"><LastName>Kahane</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y"><LastName>Chabardes</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Hirsch</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y"><LastName>Marescaux</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y"><LastName>Benazzouz</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Neurol Res</MedlineTA>
<NlmUniqueID>7905298</NlmUniqueID>
<ISSNLinking>0161-6412</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001921" MajorTopicYN="Y">Brain</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004599" MajorTopicYN="Y">Electric Stimulation Therapy</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000882" MajorTopicYN="N">Haplorhini</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020734" MajorTopicYN="N">Parkinsonian Disorders</DescriptorName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013788" MajorTopicYN="N">Thalamus</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>71</NumberOfReferences>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year>
<Month>4</Month>
<Day>19</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2000</Year>
<Month>6</Month>
<Day>10</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2000</Year>
<Month>4</Month>
<Day>19</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">10769816</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001294 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001294 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:10769816 |texte= Future prospects of brain stimulation. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:10769816" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a ParkinsonFranceV1
![]() | This area was generated with Dilib version V0.6.29. | ![]() |